High quality cancer diagnostics abroad using PEC/CT scan
PET/CT cancer diagnostic technology is advanced nuclear imaging technique that combines positron emission tomography (PET) and computed tomography (CT) into one machine.
The highly sensitive PET cancer diagnostic scan images the biology of disorders at the molecular level, while the CT scan provides a detailed picture of the body’s internal anatomy.
By combining information about the body’s metabolic function and anatomy, a PET/CT cancer diagnostic scan provides very detailed picture of cancerous tissues with high level of accuracy.
PET/CT cancer diagnostic scan has a unique ability to assess the functional and biochemical processes of the body’s tissues, which are altered in the earliest stage of disease. By identifying body changes at the cellular level, PET/CT cancer diagnostic scan may detect the early onset of cancer generally before any anatomic changes are visible on ultrasound, X-ray, MRI, or CT scan.
PET/CT cancer diagnostic scans provide valuable information to help physicians:
• Locate the site of the cancer
• Determine the size of the tumour
• Effectively pinpoint the source of cancer
• Differentiate benign from malignant growths
• Discover if the cancer has spread
• Select treatments that are likely to be appropriate
• Monitor the success of therapy
• Detect any recurrent tumours
• Select an appropriate site for biopsy
Now NHS allows you to bypass the NHS queue for PET/CT cancer diagnostic scan, by reimbursing costs of PET/CT cancer diagnostic scan, if you receive PET/CT cancer diagnostic scan in private treatment abroad.
Which Oncological Diseases are Diagnosed with the PET/CT Most Often?
The most frequently PET/CT cancer diagnostic scan is used for Hodgkin’s and non-Hodgkin lymphomas, breast cancer, colorectal and lung cancer, as well as prostate, uterine, cervical and ovarian cancer, stomach and esophageal cancer, pancreatic cancer, melanoma and sarcoma cases, as well as diagnosing the tumor of unknown location.
Prostate cancer diagnostic abroad
Prostate cancer diagnostic using PSMA PET/CT cancer diagnostic scan examination is especially crucial for those 15-20% of all prostate cancer patients whose disease relapses after previous surgery or radiation therapy – it provides precise and early diagnosis of recurrence and it is extremely important for patient counselling and treatment selection.
PET/CT cancer diagnostic scan imaging with PSMA ligand can present lesions suspicious for prostate cancer with excellent contrast and a high detection rate even when the level of prostate specific antigen is low (PSA below 1 ng/mL)
What is PSMA?
PSMA is prostate-specific membrane antigen, which is overexpressed on the surface of prostate cancer cells and can be detected even after the disease has become metastatic.
What is 68Ga?
68Ga is a positron-emitting radioisotope, which is combined with the PSMA (collectively known as 68Ga-PSMA) and injected prior to prostate cancer diagnostic scan PET/CT cancer diagnostic scan. Once administered, the agent binds to cells expressing PSMA and emits a signal detected by the PET/CT cancer diagnostic scan.
Prostate cancer diagnostic PET/CT PSMA cancer diagnostic scan is able to identify fast-growing, aggressive tumors. In addition, it may be used in place of a bone scan to painlessly determine whether prostate cancer has spread to the bone.
Prostate cancer diagnostic PET/CT PSMA cancer diagnostic scan is able to determine the extent of prostate cancer and whether it has spread to the lymph nodes or other parts of the body, unlike traditional imaging technologies such as magnetic resonance imaging (MRI) and computed tomography (CT), which are often unable to detect the spread of prostate cancer cells. Prostate cancer diagnostic using PET/CT PSMA cancer diagnostic scan helps physicians select the most effective therapy for prostate cancer, taking into account a tumor’s unique molecular properties and whether the cancer is localized or diffuse, or spread out.
PET-CT cancer diagnostic scan has proven very effective in helping physicians monitor patient response to treatment of advanced-stage prostate cancer.
PSMA specifically marks prostate cancer cells and it becomes possible to differentiate the inflammatory processes from cancer. With a single PET/CT PSMA prostate diagnostic scan it is possible to determine the existence of the metastases in soft tissues and in bones with a higher accuracy as compared to other diagnostic methods – computed tomography of prostate (CT), magnetic resonance imaging (prostate scan using MRI), scintigraphy and even has higher accuracy that Choline C-11 PET.